Metastases to central nervous system – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metastases to central nervous system – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Ipilimumab and Nivolumab with or without Radiotherapy for Patients with Melanoma Brain Metastases https://clinicaltrials.eu/trial/study-of-ipilimumab-and-nivolumab-with-or-without-radiotherapy-for-patients-with-melanoma-brain-metastases/ Wed, 29 Apr 2026 15:02:29 +0000 https://clinicaltrials.eu/trial/study-of-ipilimumab-and-nivolumab-with-or-without-radiotherapy-for-patients-with-melanoma-brain-metastases/ This clinical trial is focused on studying treatments for melanoma brain metastases, which is a condition where melanoma, a type of skin cancer, spreads to the brain. The study will use two medications: YERVOY (also known as ipilimumab) and OPDIVO (also known as nivolumab). These medications are given as a solution through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to compare the effects of using these medications alone versus using them together with a type of targeted brain radiation called stereotactic radiotherapy. This study aims to understand how these treatments can help manage the disease and improve outcomes for patients with melanoma that has spread to the brain.

Participants in the study will receive either the combination of medications and radiation or just the medications. The study will monitor the effects of these treatments over time, focusing on how they impact the brain metastases and overall health. The trial will also look at the rate of neurological-specific death, which refers to deaths caused by brain-related issues, at one year after starting treatment. The study will continue to gather information and follow participants for several years to understand the long-term effects of these treatments.

]]> Study on 68Ga-NOTA-Anti-HER2 VHH1 for Cancer Patients with Brain Metastasis https://clinicaltrials.eu/trial/study-on-68ga-nota-anti-her2-vhh1-for-cancer-patients-with-brain-metastasis/ Wed, 29 Apr 2026 15:01:15 +0000 https://clinicaltrials.eu/trial/study-on-68ga-nota-anti-her2-vhh1-for-cancer-patients-with-brain-metastasis/ This clinical trial is focused on studying patients with cancer that has spread to the brain, known as brain metastasis. The trial will use a special treatment called 68Ga-NOTA-anti-HER2 VHH1, which is a solution for injection. This treatment is designed to help doctors see how well it targets cancer cells in the brain. The purpose of the study is to compare how this treatment is taken up in brain metastasis lesions in patients who have HER2-positive cancer and those who do not.

During the study, patients will receive the 68Ga-NOTA-anti-HER2 VHH1 injection through a vein, a method known as intravenous administration. The study will observe how the treatment is absorbed by the cancer cells in the brain. This will be done by a nuclear medicine doctor who will look at images to see if the treatment is working. The doctor will not know the HER2 status of the patients to ensure unbiased results. The study will also measure the uptake of the treatment using a method called Standard Uptake Values (SUV), which helps to quantify how much of the treatment is absorbed by the cancer cells.

If possible, the study will also look at how the uptake of the treatment changes during and after any other treatments the patients might be receiving. This information will be compared to the patients’ overall disease progression. The study aims to provide valuable insights into the effectiveness of 68Ga-NOTA-anti-HER2 VHH1 in targeting brain metastasis in cancer patients, potentially leading to better treatment options in the future.

]]> Study on Nivolumab, Ipilimumab, and Bevacizumab for Patients with Non-Small Cell Lung Cancer Spread to the Brain https://clinicaltrials.eu/trial/study-on-nivolumab-ipilimumab-and-bevacizumab-for-patients-with-non-small-cell-lung-cancer-spread-to-the-brain/ Wed, 29 Apr 2026 15:00:14 +0000 https://clinicaltrials.eu/trial/study-on-nivolumab-ipilimumab-and-bevacizumab-for-patients-with-non-small-cell-lung-cancer-spread-to-the-brain/ This clinical trial is focused on studying a type of lung cancer known as non-squamous non-small-cell lung cancer (NSCLC) that has spread to the brain. The study is testing a combination of treatments to see how safe and effective they are for patients with this condition. The treatments being used in this study include nivolumab, ipilimumab, and bevacizumab, along with two cycles of chemotherapy. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to evaluate the safety and potential benefits of this new combination of treatments. Participants will receive the treatments over a period of time, and researchers will monitor them for any side effects or improvements in their condition. The study aims to understand how these treatments can help manage the cancer that has spread to the brain and improve the quality of life for patients.

Throughout the study, the medical team will keep track of any changes in the participants’ health, focusing on both the safety of the treatments and their effectiveness in controlling the cancer. The study will also look at how the treatments affect the central nervous system, which includes the brain and spinal cord. By the end of the study, researchers hope to gather valuable information that could lead to better treatment options for patients with this type of lung cancer.

]]> Study on the Effects of Losartan Potassium on Brain Tumors in Patients with Glioblastoma or Brain Metastases from Non-Small-Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-effects-of-losartan-potassium-on-brain-tumors-in-patients-with-glioblastoma-or-brain-metastases-from-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:58:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-losartan-potassium-on-brain-tumors-in-patients-with-glioblastoma-or-brain-metastases-from-non-small-cell-lung-cancer/ This clinical trial is focused on studying the effects of the medication losartan on certain types of brain tumors. The diseases being studied include glioblastoma, which is a type of brain cancer, and brain metastases from non-small-cell lung cancer (NSCLC). The treatment involves using different doses of Cozaar, which contains the active ingredient losartan potassium, available in 12.5 mg, 50 mg, and 100 mg film-coated tablets. The purpose of the study is to understand how losartan affects blood flow and the pressure caused by solid stress in brain tumors.

Participants in the study will take the medication orally over a period of time, and their progress will be monitored through various medical imaging techniques, such as MRI (Magnetic Resonance Imaging). These imaging techniques help in assessing changes in blood flow and the physical stress within the tumors. The study aims to observe how the tumors respond to the medication over time, with regular check-ups and imaging sessions scheduled throughout the study period.

The study will also track changes in the participants’ neurological performance and quality of life, using established scoring systems like the Karnofsky Performance Score (KPS) and the Eastern Cooperative Oncology Group (ECOG) scores. Additionally, the study will monitor the overall survival rates and any side effects experienced by participants during the treatment. The trial is expected to continue until the end of 2025, providing valuable insights into the potential benefits of losartan for patients with these specific brain tumors.

]]> Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-repotrectinib-for-patients-with-ros1-positive-non-small-cell-lung-cancer-and-active-brain-metastasis/ Wed, 29 Apr 2026 14:57:56 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-repotrectinib-for-patients-with-ros1-positive-non-small-cell-lung-cancer-and-active-brain-metastasis/ This clinical trial is focused on studying a type of lung cancer known as ROS1-positive non-small cell lung cancer (NSCLC) that has spread to the brain, referred to as brain metastasis. The treatment being tested in this study is a medication called Repotrectinib, also known by its code name TPX-0005. Repotrectinib is a type of drug known as a Tyrosine Kinase Inhibitor, which works by blocking certain proteins that help cancer cells grow.

The purpose of this study is to evaluate how effective Repotrectinib is in treating patients with this specific type of lung cancer that has spread to the brain. Participants in the study will take Repotrectinib in the form of a hard capsule, which is taken orally. The study will monitor the safety and effectiveness of the treatment over a period of time, with the maximum treatment period being 36 months. During the study, participants will have regular check-ups to assess their response to the treatment and to monitor any side effects.

This study aims to provide valuable information on the potential benefits of Repotrectinib for patients with ROS1-positive NSCLC with brain metastasis. The findings could help improve treatment options for this challenging condition. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]> Study Comparing Fluciclovine (18F) and Fluoroethyltyrosine F-18 PET Scans in Patients with New or Recurrent Brain Tumors and Brain Metastases https://clinicaltrials.eu/trial/study-comparing-fluciclovine-18f-and-fluoroethyltyrosine-f-18-pet-scans-in-patients-with-new-or-recurrent-brain-tumors-and-brain-metastases/ Wed, 29 Apr 2026 14:47:54 +0000 https://clinicaltrials.eu/trial/study-comparing-fluciclovine-18f-and-fluoroethyltyrosine-f-18-pet-scans-in-patients-with-new-or-recurrent-brain-tumors-and-brain-metastases-2/ This clinical trial is focused on studying brain tumors, specifically cerebral gliomas and brain metastases. The trial involves patients who have been newly diagnosed with these conditions or have experienced a recurrence. The study will use two different imaging agents, 18F-Fluciclovine and 18F-Fluoroethyltyrosine, both of which are solutions for injection. These agents help in visualizing the tumors during a type of scan called a PET scan, which stands for Positron Emission Tomography. The purpose of the study is to compare how well these two agents work in showing the size and spread of the tumors in the brain.

Participants in the study will receive injections of these imaging agents, and then undergo PET scans. The study will look at how the images from the two different agents compare in terms of showing the tumor’s size and how the agent spreads in the brain. This will help doctors understand which agent might be more effective for certain types of brain tumors. The study is designed to be open-label, meaning both the participants and the researchers know which agent is being used.

The trial aims to gather information over a period of time to see if there is a significant correlation between the results from the two agents. It will also assess how accurately these agents can differentiate between tumor growth and changes related to previous treatments. This information could be valuable in improving the diagnosis and treatment planning for patients with brain tumors.

]]> Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-for-patients-with-her2-low-breast-cancer-and-new-or-worsening-brain-metastases/ Wed, 29 Apr 2026 14:29:07 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-for-patients-with-her2-low-breast-cancer-and-new-or-worsening-brain-metastases/ This clinical trial is focused on studying a type of breast cancer known as HER2-low breast cancer, which has spread to the brain, a condition referred to as brain metastases. The study is investigating the effects of a treatment called Trastuzumab Deruxtecan, also known by its code name DS-8201a. This treatment is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective this treatment is for patients with HER2-low breast cancer that has either been newly diagnosed or is progressing in the brain. Participants in the study will receive the treatment and be monitored over time to see how their cancer responds. The study will also include a comparison with a placebo to better understand the treatment’s effects. The trial will last for a period of time, during which participants will have regular check-ups and assessments to track their progress and any changes in their condition.

Throughout the study, the focus will be on understanding the treatment’s impact on the cancer in the brain, as well as any side effects or changes in the participants’ quality of life. The study aims to provide valuable information that could help improve treatment options for patients with this specific type of breast cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases https://clinicaltrials.eu/trial/study-on-bevacizumab-and-prednisolone-for-patients-with-brain-radionecrosis-after-radiotherapy-for-brain-metastases/ Wed, 29 Apr 2026 14:28:51 +0000 https://clinicaltrials.eu/trial/study-on-bevacizumab-and-prednisolone-for-patients-with-brain-radionecrosis-after-radiotherapy-for-brain-metastases/ This study focuses on patients with brain radionecrosis, a condition where brain tissue is damaged following radiation therapy for brain metastases. The study aims to determine if adding bevacizumab to standard treatment with corticosteroids is more effective than using corticosteroids with placebo in treating symptoms of brain radionecrosis.

The treatment involves a combination of medications including prednisolone tablets (a corticosteroid medication), sodium chloride solution for infusion, and bevacizumab (also known as Avastin) given through an intravenous infusion. The study medication or placebo will be given along with standard corticosteroid therapy for three months.

During the study, doctors will monitor how well the treatment works by measuring changes in corticosteroid dose requirements and evaluating neurological symptoms. They will also track changes in the brain using medical imaging and assess the patient’s quality of life. The total duration of monitoring after treatment will continue for up to two years to observe long-term effects of the treatment.

]]> Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers https://clinicaltrials.eu/trial/study-of-azd9574-and-temozolomide-for-patients-with-advanced-solid-tumors-including-breast-ovarian-pancreatic-and-prostate-cancers/ Wed, 29 Apr 2026 14:28:05 +0000 https://clinicaltrials.eu/trial/study-of-azd9574-and-temozolomide-for-patients-with-advanced-solid-tumors-including-breast-ovarian-pancreatic-and-prostate-cancers/ This clinical trial is focused on studying the effects of a new treatment for patients with advanced solid tumors. The study involves a medication called AZD9574, which is being tested both on its own and in combination with other anti-cancer treatments. The diseases being studied include IDH-mutant glioma, a type of brain tumor, and various advanced or relapsed cancers such as HER2-negative breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer. These cancers may have specific genetic mutations like BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.

The purpose of the study is to assess the safety and tolerability of AZD9574 in patients with these advanced cancers. Participants will receive the medication in the form of a film-coated tablet taken orally. The study will monitor how the body processes the drug, its effects on the cancer, and any side effects that may occur. Some participants may receive a placebo for comparison. The study will also explore how the drug affects specific biomarkers, which are indicators of how the body is responding to the treatment.

Throughout the study, participants will undergo regular health checks, including blood tests and imaging scans, to track their progress and the impact of the treatment. The study aims to gather information over a period of time to determine the potential benefits and risks of AZD9574 for treating these types of cancers. This research is important for developing new treatment options for patients with advanced solid tumors.

]]> Study of Patritumab Deruxtecan for Patients with Brain Metastases from Advanced Breast or Lung Cancer and Leptomeningeal Disease from Solid Tumors https://clinicaltrials.eu/trial/study-of-patritumab-deruxtecan-for-patients-with-brain-metastases-from-advanced-breast-or-lung-cancer-and-leptomeningeal-disease-from-solid-tumors/ Wed, 29 Apr 2026 14:26:33 +0000 https://clinicaltrials.eu/trial/study-of-patritumab-deruxtecan-for-patients-with-brain-metastases-from-advanced-breast-or-lung-cancer-and-leptomeningeal-disease-from-solid-tumors/ This clinical trial is focused on studying the effects of a treatment called Patritumab deruxtecan, also known by its code name HER3-DXd. The study is designed for patients with certain types of cancer, specifically those with advanced breast cancer and non-small cell lung cancer that have spread to the brain, as well as patients with leptomeningeal carcinomatosis, a condition where cancer spreads to the membranes surrounding the brain and spinal cord. The purpose of the study is to evaluate how well this treatment works in these specific conditions.

Participants in the study will receive Patritumab deruxtecan as a solution through an intravenous infusion, which means it will be administered directly into the bloodstream. The study is organized into three groups, or cohorts, each focusing on different aspects of the treatment’s effectiveness. The first two groups will look at how the treatment affects brain metastases, which are cancerous growths that have spread to the brain. The third group will focus on patients with leptomeningeal carcinomatosis, assessing their overall survival rate after three months of treatment.

The study will take place over a period of time, with regular monitoring to observe the treatment’s effects. Participants will undergo various assessments, including imaging tests like MRI to track changes in their condition. The study aims to provide valuable information on the potential benefits of Patritumab deruxtecan for patients with these challenging cancer conditions.

]]> Study on JDQ443 for Patients with KRAS G12C+ Non-Small Cell Lung Cancer and Brain Metastases https://clinicaltrials.eu/trial/study-on-jdq443-for-patients-with-kras-g12c-non-small-cell-lung-cancer-and-brain-metastases/ Wed, 29 Apr 2026 14:26:03 +0000 https://clinicaltrials.eu/trial/study-on-jdq443-for-patients-with-kras-g12c-non-small-cell-lung-cancer-and-brain-metastases/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC) that has a specific mutation called KRAS G12C. The study also involves patients whose cancer has spread to the brain, known as brain metastases. The treatment being tested is a medication called JDQ443, which is taken in tablet form. The purpose of the study is to evaluate how well JDQ443 works in treating brain metastases in these patients.

Participants in the study will receive JDQ443 and will be monitored to see how their brain metastases respond to the treatment. The study will look at how the cancer in the brain changes over time and whether the treatment can control the disease. The study will also assess the overall health and quality of life of the participants during the treatment period.

The study will last for a period of up to 12 months, during which participants will take the medication and undergo regular check-ups to monitor their condition. The results will help determine the effectiveness of JDQ443 in treating brain metastases in patients with KRAS G12C-positive NSCLC. This research aims to provide valuable information that could lead to better treatment options for patients with this type of cancer.

]]> Study of SGM-101 fluorescent antibody to detect brain metastases from colorectal cancer during surgery https://clinicaltrials.eu/trial/study-on-sgm-101-for-detecting-brain-metastases-in-colorectal-cancer-patients/ Wed, 29 Apr 2026 14:23:02 +0000 https://clinicaltrials.eu/trial/study-on-sgm-101-for-detecting-brain-metastases-in-colorectal-cancer-patients/ This study focuses on patients with brain metastases that have spread from colorectal cancer. The research evaluates a new imaging method using SGM-101, which is a special solution for injection. This medication is a fluorescent antibody that attaches to specific markers found on cancer cells, making them visible during surgery.

The purpose of the study is to determine how well SGM-101 can help surgeons detect and locate brain metastases during surgery. The medication is given through intravenous infusion before the surgical procedure. During the operation, doctors use a special camera system called the Quest Spectrum System to see the areas where the fluorescent medication has attached to cancer cells.

The study treatment involves a single dose of up to 15 milligrams of SGM-101. After receiving the medication, patients will undergo their planned brain surgery while doctors use the fluorescent imaging system. The study will monitor patients’ recovery and any side effects that may occur after the procedure.

]]>